- Condition: Healthy
Interventions: Drug: theophylline; Drug: colchicine
Sponsors: Mutual Pharmaceutical Company, Inc.; Mutual Pharmaceutical Company, Inc.
Not yet recruiting - verified May 2012 - Conditions: Restenosis; Peripheral Arterial Disease
Interventions: Drug: Paclitaxel; Drug: Placebo
Sponsors: Midwest Cardiovascular Research Foundation; Midwest Cardiovascular Research Foundation; Spectranetics Corporation
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Not yet recruiting - verified May 2012 - Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Patients Must Have Histologically or Cytologically Confirmed Non-squamous Cell, Non Small Cell Carcinoma of the Lung.; Patient Must Have Measurable Stage IV Disease (Includes M1a, M1b Stages or Recurrent Disease).
Interventions: Drug: Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Drug: Paclictaxl, Carboplatin, and Bevcizumab.
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: BKM120; Drug: Paclitaxel; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Drug: Part 1, Cohort 1; Drug: Part 1, Cohort 2; Drug: Part 1, Cohort 3; Drug: Part 2, Cohort 1; Drug: Part 2, Cohort 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting - verified May 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Drug: nab-paclitaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Chemoradiation; Radiation: Chemoradiation; Procedure: Quality-of-life assessment
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease
Interventions: Drug: Abraxane; Drug: Abraxane; Drug: Abraxane; Drug: Abraxane
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Small -Cell Lung Cancer
Interventions: Drug: Veliparib; Drug: Carboplatin; Drug: paclitaxel; Drug: placebo
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Metastatic Medulloblastoma; High Risk Supratentorial PNET; Metastatic PNET
Interventions: Drug: Carboplatin; Drug: Vincristine; Radiation: 24 Gy
Sponsors: Children's Hospital Colorad; Children's Hospital Colorad
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; Genentech
Not yet recruiting - verified March 2012 - Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Adriamycin, vinblastine, and dacarbazine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Seattle Genetics, Inc.
Recruiting - verified April 2012 - Conditions: Solid Tumors; Primary Brain Tumors
Interventions: Drug: Vincristine sulfate; Drug: Irinotecan; Drug: Temozolomide; Drug: Metformin
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation
Not yet recruiting - verified April 2012 - Condition: Advanced, Incurable Solid Tumors
Interventions: Drug: PLX3397 + Paclitaxel; Drug: PLX3397 + Paclitaxel; Drug: PLX3397 + Paclitaxel; Drug: PLX3397 + Paclitaxel
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Everolimus; Drug: Prednisone; Drug: Vincristine; Drug: PEG-Asparaginase; Drug: Doxorubicin; Drug: Dexrazoxane
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Novartis
Recruiting - verified January 2012 - Conditions: Inflammatory Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Malignant Solid Tumor
Interventions: Biological: ramucirumab (IMC-1121B); Drug: paclitaxel
Sponsors: ImClone LLC; ImClone LLC
Not yet recruiting - verified May 2012 - Condition: Metastatic Melanoma
Interventions: Drug: vinblastine; Drug: Cyclophosphamide; Drug: dacarbazine
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified February 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Acute Lymphoblastic Leukemia; Neuropathy; Neuropathic Pain
Interventions: Drug: gabapentin; Drug: placebo
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: TAC chemotherapy; Drug: TC chemotherapy; Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy; Drug: TCH chemotherapy
Sponsors: Agendia; Agendia; University of South Florida; University of Miami
Recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Condition: Low-grade Glioma
Intervention: Drug: Weekly vinorelbine treatment
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified February 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Not yet recruiting - verified March 2012 - Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: mifepristone; Drug: placebo; Drug: nab-paclitaxel
Sponsors: University of Chicago; Rita Nanda
Recruiting - verified December 2011 - Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012 - Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: Oral azacitidine plus Abraxane; Drug: Carboplatin; Drug: Abraxane
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012 - Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: FOLFIRINOX; Genetic: Immunohistochemistry (IHC) Analysis; Drug: Metformin
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team
Recruiting - verified March 2012 - Condition: Prostate Cancer
Intervention: Drug: Colchicine
Sponsors: Penn State University; Penn State University
Not yet recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Chemotherapy; Drug: Chemotherapy and ChemoRadiotherapy
Sponsors: University of Florida; University of Florida
Recruiting - verified February 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: vincristine
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified March 2012 - Conditions: Esophageal Cancer; Neoplasms, Esophageal
Interventions: Drug: Everolimus; Drug: Paclitaxel; Drug: carboplatin; Drug: cetuximab
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified March 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin; Drug: doxorubicin hydrochloride; Drug: vinblastine; Drug: dacarbazine; Procedure: quality-of-life assessment; Genetic: DNA analysis; Genetic: RNA analysis; Radiation: fludeoxyglucose F 18; Procedure: positron emission tomography; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymorphism analysis
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified November 2011 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel); Drug: Gemcitabine
Sponsors: ParinGenix; ParinGenix; TGen Drug Development Services
Recruiting - verified April 2012 - Condition: Intercritical Gout
Interventions: Drug: Colchicine; Drug: Placebo; Drug: Allopurinol
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: MM-121 (SAR256212) + Paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Inoperable Locally Advanced Breast Cancer; Metastatic Breast Cancer (MBC)
Intervention: Drug: BEZ235 + Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified September 2011 - Condition: Pleuropulmonary Blastoma
Interventions: Drug: Vincristine; Drug: Dactinomycin; Drug: Cyclophosphamide; Drug: Ifosfamide; Drug: Doxorubicin
Sponsors: Children's Hospitals and Clinics of Minnesota; Children's Hospitals and Clinics of Minnesota
Recruiting - verified November 2011 - Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: afatinib; Drug: afatinib; Drug: Vinorelbine; Drug: Investigator's choice of treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Acute Lymphoblastic Leukemia (ALL)
Interventions: Drug: Vincristine Sulfate Liposomes Injection (VSLI); Drug: Vincristine Sulfate Injection (VSI)
Sponsors: Talon Therapeutics, Inc; Talon Therapeutics, Inc
Recruiting - verified May 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ponatinib; Drug: G-CSF (Filgrastim); Drug: Rituximab; Drug: Methotrexate; Drug: Cytarabine; Drug: Solu-medrol ( Methyl Prednisolone); Drug: Citrovorum (Leucovorin); Drug: Prednisone; Drug: Pegfilgrastim (Neulasta)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Biological: trastuzumab; Drug: Neratinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Pfizer
Recruiting - verified March 2012 - Conditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) plus paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified April 2012 - Conditions: Lymphoma, Diffuse Large-Cell B-cell; Diffuse, Large B-cell Lymphoma; Lymphoma, Diffuse Large-Cell; Large-Cell Lymphoma, Diffuse
Interventions: Drug: MLN4924; Drug: Etoposide; Drug: Prednisone; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Rituximab; Drug: Filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Constipation
Interventions: Other: Opioid Dose Intervention; Other: Opioid Assessment Intervention; Other: Vinca Alkaloid Assessment Intervention
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Institutes of Health (NIH); University of South Florida
Recruiting - verified January 2012 - Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel; Drug: carboplatin; Drug: vorinostat; Other: placebo; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: protein analysis; Genetic: gene expression analysis; Genetic: proteomic profiling
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab; Drug: Nab-paclitaxel; Drug: Carboplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Celgene Corporation
Recruiting - verified February 2012 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Lymphoma; Neurotoxicity; Radiation Toxicity
Interventions: Biological: rituximab; Drug: cytarabine; Drug: methotrexate; Drug: procarbazine hydrochloride; Drug: vincristine sulfate; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Unspecified Adult Solid Tumor - Protocol Specific; Breast Cancer - Female
Interventions: Drug: Pazopanib; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI); GlaxoSmithKline
Recruiting - verified September 2011 - Conditions: Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma; Mantle Cell Lymphoma; Burkitt's Lymphoma
Intervention: Drug: Alisertib (MLN8237) + Rituximab + Vincristine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction
Interventions: Drug: Carboplatin AUC; Drug: Paclitaxel; Drug: lapatinib
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: placebo
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Esophageal Cancer
Interventions: Drug: Paclitaxel with Cisplatin; Drug: Arm B
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified June 2011 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Mesna; Drug: Vincristine; Drug: Dexamethasone; Drug: Pegfilgrastim; Drug: Methotrexate; Drug: Ara-C; Drug: Inotuzumab Ozogamycin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012 - Condition: Uterine Carcinosarcoma
Intervention: Drug: Paclitaxel, Carboplatin and Radiation
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified June 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel; Drug: Trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified January 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: MK-1775; Drug: Placebo; Drug: paclitaxel; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Breast Cancer; Metastatic Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Capecitabine; Drug: Motesanib
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Susan G. Komen Breast Cancer Foundation; Amgen
Not yet recruiting - verified January 2012 - Conditions: Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: hypofractionated radiation therapy; Other: laboratory biomarker analysis; Radiation: image-guided radiation therapy; Drug: carboplatin; Drug: paclitaxel; Radiation: stereotactic body radiation therapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: Tamibarotene; Drug: Placebo
Sponsors: CytRx; CytRx
Recruiting - verified March 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: everolimus; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Ovarian Cancer Recurrent
Interventions: Drug: Ombrabulin (AVE8062); Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: FOLFOX regimen; Drug: carboplatin; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Peripheral Vascular Disease
Intervention: Drug: Paclitaxel
Sponsors: Sanford Health; Patrick Kelly
Recruiting - verified March 2012 - A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesCondition: Cancer
Intervention: Drug: BBI608 and paclitaxel
Sponsors: Boston Biomedical, Inc; Boston Biomedical, Inc
Recruiting - verified February 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Metformin; Drug: Vincristine; Drug: Dexamethasone; Drug: PEG-asparaginase; Drug: Doxorubicin; Drug: Intrathecal chemotherapy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation
Recruiting - verified April 2012 - Conditions: Advanced Solid Tumors; Kidney Disease; Renal Impairment
Interventions: Drug: AMG 386 + Paclitaxel; Drug: AMG 386
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma
Interventions: Drug: prednisone; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Drug: pralatrexate; Other: laboratory biomarker analysis; Genetic: comparative genomic hybridization; Genetic: gene expression analysis; Genetic: nucleic acid sequencing; Genetic: mutation analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: RNA analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Radiation: Radiation; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: PD0332991; Drug: Paclitaxel
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012 - Condition: Neuroblastoma
Intervention: Drug: Metaiodobenzylguanidine (MIBG)
Sponsors: University of California, San Francisco; University of California, San Francisco; Thrasher Research Fund
Recruiting - verified September 2011 - Condition: Peripheral Neuropathy
Intervention: Dietary Supplement: Alpha lipoic acid
Sponsors: Northwestern University; Northwestern University
Not yet recruiting - verified June 2011 - Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Biological: cetuximab; Drug: paclitaxel; Drug: carboplatin; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Procedure: biopsy
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Belionstat, Carboplatin, Paclitaxel
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; TopoTarget A/S
Recruiting - verified May 2012 - Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Vinorelbine; Drug: Trastuzumab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Solid Tumor in Advanced Stage
Intervention: Drug: Paclitaxel Injection Concentrate for Nanodispersion
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified August 2011 - Condition: Solid Tumor in Advanced Stage
Intervention: Drug: Paclitaxel Injection Concentrate for Nanodispersion
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified August 2011 - Condition: Advanced Solid Malignances
Interventions: Drug: INK128, paclitaxel, trastuzumab; Drug: INK128, paclitaxel, trastuzumab
Sponsors: Intellikine; Intellikine
Recruiting - verified February 2012 - Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: GDC-0980; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Condition: HER-2 Gene Amplification
Interventions: Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111; Drug: Lapatinib, Trastuzumab and MM-111; Drug: Paclitaxel, Trastuzumab and MM-111
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012 - Condition: Solid Tumors
Interventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin; Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Resectable Pancreatic Cancer
Intervention: Drug: Abraxane plus Gemcitabine
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team; Celgene Corporation
Recruiting - verified November 2011 - Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: carboplatin-Taxol regimen; Drug: cisplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Cancer
Interventions: Drug: GSK1120212; Drug: Docetaxel + GSK1120212; Drug: Erlotinib + GSK1120212; Drug: Pemetrexed + GSK1120212; Drug: Carboplatin + GSK1120212; Drug: Nab-paclitaxel + GSK1120212; Drug: Gemcitabine + GSK1120212; Drug: Everolimus + GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma; Neuroblastoma; Sarcoma; Desmoplastic Small Round Cell Tumor
Interventions: Drug: Melphalan; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: Etoposide; Drug: Filgrastim; Biological: NK-DLI Infusions
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: HER2-negative Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: paclitaxel; Biological: bavituximab; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Cervical Cancer
Interventions: Drug: cisplatin; Drug: paclitaxel; Drug: veliparib; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cilengitide; Drug: paclitaxel; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCondition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866; Drug: Gemcitabine and Carboplatin; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; University of Pennsylvania
Recruiting - verified April 2012 - Condition: CNS Germ Cell Tumor
Intervention: Drug: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified February 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Procedure: tumor biopsy and blood draw
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0980; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2012 - Conditions: Endometrial Cancer; Ovarian Cancer
Interventions: Drug: Ridaforolimus; Drug: Paclitaxel; Drug: carboplatin
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Recruiting - verified April 2012 - Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011 - A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid TumorsCondition: Solid Tumors
Intervention: Drug: LCL161
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: carboplatin; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: paclitaxel; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Advanced Solid Tumors; Tumors; Cancer
Interventions: Drug: MK-2206; Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: University of California, San Francisco; University of California, San Francisco; Merck
Recruiting - verified March 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Chemotherapeutic Agent Toxicity; Pain; Peripheral Neuropathy; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Therapy-related Toxicity
Interventions: Procedure: cryotherapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Procedure: management of therapy complications; Procedure: assessment of therapy complications
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Sarcoma; Neuroblastoma; Wilms Tumor; Leukemia; Lymphoma; Brain Tumors
Intervention: Drug: Marqibo
Sponsors: Talon Therapeutics, Inc; Talon Therapeutics, Inc; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Transitional Cell Carcinoma; Bladder Carcinoma; Urothelial Carcinoma
Interventions: Drug: Everolimus; Drug: Everolimus; Drug: Paclitaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Lung Cancer; Non Small Cell Lung Carcinoma; Hypermethylation
Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel; Drug: Vidaza; Procedure: Tumor Specimen for Methylation Analysis; Procedure: Blood Sample for Methylation Analysis; Drug: Vinorelbine; Drug: Docetaxel; Drug: Pemetrexed
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified October 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Abraxane; Drug: Carboplatin
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified September 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: wild-type reovirus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Melanoma
Interventions: Drug: Genasense; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genta Incorporated
Recruiting - verified April 2012 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Melanoma (Skin)
Interventions: Drug: cisplatin; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temozolomide; Drug: vinblastine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Biological: rituximab; Drug: EPOCH regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention: Drug: Sorafenib
Sponsors: Emory University; Emory University; Onyx Pharmaceuticals; Bayer
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Drug: Trametinib (GSK1120212); Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel; Drug: Cisplatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Advanced Cancer
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Sorafenib; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Pazopanib plus Paclitaxel
Sponsors: Loyola University; Loyola University; GlaxoSmithKline
Recruiting - verified September 2011 - Condition: Neuroblastoma
Interventions: Drug: busulfan; Drug: cisplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: isotretinoin; Drug: melphalan; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Other: pharmacological study; Other: questionnaire administration; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: iobenguane I 131
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Melanoma
Interventions: Drug: Axitinib; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: University of California, San Francisco; Adil Daud
Recruiting - verified January 2012 - Condition: Gastric Cancer
Interventions: Biological: Ramucirumab DP; Drug: Placebo; Drug: Paclitaxel
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Drug: paclitaxel
Sponsors: University of Kansas; University of Kansas; Novartis
Recruiting - verified October 2011 - Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012 - Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Cetuximab; Drug: Cetuximab; Drug: Docetaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiotherapy (RT); Other: Chemotherapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: cixutumumab; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin; Other: Isotonic saline (perfusate); Procedure: Surgery; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Drug: Carboplatin, paclitaxel, and bevacizumab
Sponsors: Columbia University; Columbia University; Genentech
Recruiting - verified October 2011 - Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaConditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: bortezomib; Drug: mitoxantrone hydrochloride; Drug: etoposide; Drug: cytarabine; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: Nab-paclitaxel; Drug: Bevacizumab; Drug: Gemcitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions: Drug: Pazopanib (GW786034); Drug: Paclitaxel
Sponsors: Stanford University; Sandy Srinivas; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Estrogen Receptor-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method; Genetic: gene expression analysis; Drug: veliparib; Drug: cisplatin; Drug: vinorelbine tartrate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: NSCLC; Solid Tumors
Interventions: Drug: YM155; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: filgrastim; Drug: plerixafor; Biological: rituximab; Drug: ifosfamide; Drug: carboplatin; Drug: etoposide; Procedure: leukapheresis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Cetuximab; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System; Bristol-Myers Squibb
Recruiting - verified June 2011 - Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel; Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Stages II-III Breast Cancer
Interventions: Drug: Nanoparticle Albumin Bound Paclitaxel; Drug: doxorubicin; Drug: cyclophosphamide
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011 - Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified September 2011 - Conditions: Leukemia, Myelogenous, Acute; Myelodysplastic Syndromes
Intervention: Drug: OXi4503
Sponsors: University of Florida; University of Florida; The Leukemia and Lymphoma Society
Recruiting - verified March 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Drug: ixabepilone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011 - Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Stand Up To Cancer; Genentech; Celgene Corporation
Recruiting - verified March 2012 - Conditions: Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer
Interventions: Drug: Pazopanib; Drug: Vinorelbine
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified October 2011 - Condition: Advanced Cancers
Interventions: Drug: HAI Abraxane; Drug: Gemcitabine; Drug: Bevacizumab; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone; Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2012 - Conditions: Hemangiosarcoma; Soft Tissue Sarcoma
Intervention: Drug: Paclitaxel in combination with Bevacizumab
Sponsors: Stanford University; Stanford University; Genentech
Recruiting - verified February 2012 - Conditions: Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: acupuncture therapy; Drug: paclitaxel; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012 - Condition: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: ixabepilone; Drug: bevacizumab
Sponsors: Providence Health & Services; Providence Health & Services; Genentech; Bristol-Myers Squibb
Recruiting - verified July 2011 - Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Melanoma
Intervention: Drug: LOC-paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Luitpold Pharmaceuticals
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Panitumumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Amgen
Recruiting - verified April 2012 - Conditions: Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide; Drug: Etoposide; Drug: Alemtuzumab; Drug: Doxorubicin; Drug: Prednisone; Drug: Filgrastim; Drug: Rituximab; Drug: Vincristine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Intervention: Drug: single arm dose dense MVAC
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center
Recruiting - verified March 2012 - Conditions: Squamous Cell Cancer; Head and Neck Cancer
Intervention: Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; NATL COMP CA NETWORK; Pfizer
Recruiting - verified January 2012 - Condition: Advanced Cancer
Interventions: Drug: Dasatinib; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified April 2012 - Conditions: Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: panitumumab; Drug: paclitaxel; Drug: carboplatin; Procedure: laboratory biomarker analysis; Procedure: immunohistochemistry staining method
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: vincristine sulfate; Other: pharmacological study
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2011 - Condition: Leukemia-Lymphoma, Adult T-Cell
Intervention: Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012 - Condition: Carcinoma
Interventions: Biological: REOLYSIN; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Oncolytics Biotech; Oncolytics Biotech; University of Texas
Recruiting - verified December 2011 - Condition: Melanoma
Intervention: Drug: paclitaxel, carboplatin, temozolomide
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Refractory Solid Tumors in Children
Intervention: Drug: combination of Irinotecan, vincristine, temozolomide and bevacizumab
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified October 2009 - Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Radiation: Involved field irradiation
Sponsors: Fondazione Michelangelo; Fondazione Michelangelo
Recruiting - verified February 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Metastatic Melanoma
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Oncolytics Biotech; Oncolytics Biotech; University of Texas
Recruiting - verified October 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Cyclosporins; Drug: nab-paclitaxel
Sponsors: Northwestern University; Northwestern University; Avon Foundation
Recruiting - verified May 2012 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Ovarian Neoplasms
Interventions: Drug: Vorinostat; Drug: Vorinostat
Sponsors: Gynecologic Oncology Associates; Gynecologic Oncology Associates; Merck
Recruiting - verified June 2011 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: PEG-asparaginase; Drug: Cytarabine; Drug: Methotrexate; Drug: Imatinib; Drug: Clofarabine; Drug: 6 Mercaptopurine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Enzon Pharmaceuticals, Inc.; Genzyme
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: GDC-0941; Drug: paclitaxel; Drug: pemetrexed; Drug: cisplatin
Sponsors: Genentech; Genentech
Recruiting - verified November 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Solu-Medrol; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified November 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel; Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel
Sponsors: BioNumerik Pharmaceuticals, Inc.; BioNumerik Pharmaceuticals, Inc.
Recruiting - verified January 2011 - Condition: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0941; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: nab-paclitaxel; Drug: trastuzumab; Drug: Doxorubicin; Drug: cyclophosphamide
Sponsors: University of Kansas; University of Kansas; Celgene Corporation
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: everolimus; Drug: abraxane
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: everolimus; Drug: paclitaxel; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Cervical Carcinoma; Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Carcinoma, Non-SquamousType
Intervention: Drug: Ixempra (Ixbepilone (BMS-247550) )
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib; Drug: Ixabepilone
Sponsors: Accelerated Community Oncology Research Network; Accelerated Community Oncology Research Network; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012 - Condition: Leukemia, Lymphocytic, Acute
Interventions: Drug: Methotrexate; Drug: Vincristine; Drug: PEG-l-asparaginase; Drug: Dexamethasone; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib; Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Pfizer
Recruiting - verified March 2012 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Ixabepilone; Drug: Sunitinib; Other: Angiogenesis Biomarker Analysis; Other: Pharmacokinetic Design
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center; Bristol-Myers Squibb; Pfizer
Recruiting - verified March 2012 - Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cytarabine; Drug: decitabine; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: gemcitabine hydrochloride; Drug: vinorelbine ditartrate
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: 3 Dimensional Proton Radiotherapy; Drug: Paclitaxel and Carboplatin; Procedure: Surgery (if applicable); Drug: Paclitaxel and Carboplatin
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Conditions: Solid Tumors; Ovarian Cancer
Interventions: Drug: OSI-906; Drug: Paclitaxel
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012 - Conditions: Neuroblastoma; Bone Marrow, Sympathetic Nervous System
Intervention: Other: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Biological: Imprime PGG® Injection; Biological: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Biothera; Biothera
Recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Radiation: Conformal radiation
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Interventions: Drug: Daunorubicin; Drug: Vincristine; Drug: PEG-asparaginase; Drug: Intrathecal Methotrexate; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Doxorubicin; Drug: Thioguanine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Carcinoma, Non-small Cell Lung
Interventions: Biological: REOLYSIN®; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified May 2011 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Conditions: Melanoma; Liver Metastasis
Intervention: Drug: Nab-Paclitaxel (Abraxane)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib and Ixabepilone; Drug: Sorafenib and Ixabepilone
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Bayer; Bristol-Myers Squibb
Recruiting - verified October 2011 - Conditions: Ovarian Cancer; Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting - verified December 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer
Interventions: Drug: imiquimod; Drug: Abraxane; Other: laboratory biomarker analysis; Genetic: RNA analysis; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Atherosclerosis; Angioplasty; Peripheral Arterial Disease
Intervention: Drug: Paclitaxel
Sponsors: University of Oklahoma; University of Oklahoma
Recruiting - verified August 2011 - Conditions: Urothelial Cancer; Muscle-invasive Urothelial Carcinoma
Interventions: Drug: Methotrexate; Drug: Doxorubicin; Drug: vinblastine; Drug: cisplatin; Drug: Pegfilgrastim
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Amgen
Recruiting - verified February 2012 - Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Hodgkin's Disease
Interventions: Drug: R-mabHD; Drug: ABVD
Sponsors: American Scitech International; American Scitech International; ImClone LLC; Bristol-Myers Squibb
Not yet recruiting - verified July 2011 - Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: lapatinib ditosylate; Drug: paclitaxel; Drug: vinorelbine ditartrate; Drug: Trastuzumab
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat); Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified April 2012 - Condition: Solid Tumor
Interventions: Drug: Bevacizumab; Drug: Temozolomide; Drug: Vincristine sulfate; Drug: Irinotecan; Drug: Cefixime or Cefpodoxime
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Celgene Corporation; Genentech
Recruiting - verified February 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Cancer; Non-Small Cell Lung Cancer; Endometrial Carcinoma; Ovarian Carcinoma
Interventions: Drug: XL147 (SAR245408),; Drug: paclitaxel; Drug: carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Conditions: Advanced or Metastatic Solid Tumors; Advanced or Metastatic Breast Cancer
Interventions: Drug: Azacitidine (Vidaza); Drug: Nab-paclitaxel (Abraxane)
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011 - Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Biological: bevacizumab; Drug: erlotinib hydrochloride; Other: immunohistochemistry staining method; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Hodgkin Lymphoma
Intervention: Drug: Avastin
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Genentech
Recruiting - verified November 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsors: Agennix; Agennix
Recruiting - verified March 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel; Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Sponsors: Penn State University; Penn State University
Recruiting - verified July 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: lenalidomide; Drug: prednisone; Drug: vincristine sulfate; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Rituximab; Drug: Cyclophosphamide (CTX); Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Methotrexate (MTX); Drug: Cytarabine; Drug: G-CSF; Drug: Mesna; Drug: Pegylated asparaginase; Drug: Pegfilgrastim; Drug: Solumedrol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Burkitt's Lymphoma; Burkitt'S-like Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: G-CSF; Drug: Cytarabine; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Peritoneal Neoplasms
Intervention: Drug: nanoparticulate paclitaxel
Sponsors: CritiTech, Inc.; CritiTech, Inc.; University of Kansas Medical Center Research Institute, Inc.; Beckloff Associates, Inc.
Recruiting - verified April 2012 - Condition: Carcinoma, Squamous Cell
Interventions: Drug: paclitaxel poliglumex; Biological: cetuximab; Radiation: radiation therapy (IMRT or 3D-CRT)
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Cell Therapeutics
Recruiting - verified April 2012 - Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ABI-007l albumin-stabilized nanoparticle formulation
Sponsors: Loyola University; Loyola University; Genentech
Recruiting - verified September 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel; Drug: Gemcitabine; Biological: Avastin
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Genentech
Recruiting - verified August 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Drug: Adriamycin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2012 - Conditions: Lymphoma, B-Cell; Follicular Lymphoma
Intervention: Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone
Sponsors: Emory University; Emory University; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: nab-paclitaxel; Drug: trastuzumab
Sponsors: Brown University; Debora G. Isdale; Yale University
Recruiting - verified February 2012 - Conditions: Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: vinorelbine tartrate; Drug: paclitaxel; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Bladder Cancer
Intervention: Drug: Paclitaxel, nanoparticle albumin-bound
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Myelodysplastic Syndrome; Hodgkin's Lymphoma; Non-Hodgkin's Disease; Acute Leukemia; Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Biological: rituximab; Drug: Methotrexate; Drug: Sirolimus; Drug: Cyclosporine; Drug: Doxorubicin hydrochloride; Drug: Etoposide; Drug: Fludarabine phosphate; Drug: Prednisone; Drug: Vincristine sulfate; Drug: Cytarabine; Drug: Tacrolimus; Biological: Alemtuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate; Drug: paclitaxel; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: filgrastim; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Metastatic Malignant Uveal Melanoma
Intervention: Drug: Marqibo® (vincristine sulfate liposomes injection)
Sponsors: Talon Therapeutics, Inc; Talon Therapeutics, Inc
Recruiting - verified September 2011 - Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Peritoneal Cancer
Interventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Abraxane; Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Duke University; Duke University; Genentech
Recruiting - verified June 2011 - Conditions: Mantle Cell Lymphoma; Lymphoma
Interventions: Drug: Bortezomib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Methotrexate; Drug: Cytarabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Doxorubicin; Drug: Cytarabine; Drug: Methotrexate; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Methylprednisone; Drug: Hydrocortisone Sodium Succinate; Drug: Dexamethasone; Drug: 6-MP; Drug: PEG-Asparaginase; Drug: Imatinib; Drug: Etoposide; Procedure: Radiation Therapy; Drug: E. coli Asparaginase
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Children's Hospital Boston
Recruiting - verified August 2011 - Conditions: Non-Small Cell Lung Cancer; Venous Thromboembolism
Intervention: Drug: Carboplatin, Paclitaxel, Arixtra
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified July 2011 - Conditions: Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Drug: pemetrexed disodium
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Genetic: RNA-based gene array studies; Genetic: Real time PCR gene expression studies; Genetic: Tissue-array immunohistochemical studies; Genetic: Immunoglobulin G Fc receptor genotypes determination
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Taxol (paclitaxel); Procedure: Radiotherapy; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Leo W. Jenkins Cancer Center; Leo W. Jenkins Cancer Center
Recruiting - verified January 2012 - Conditions: Childhood Germ Cell Tumor; Ovarian Cancer; Teratoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: ifosfamide; Drug: paclitaxel; Drug: thiotepa; Procedure: autologous hematopoietic stem cell transplantation; Drug: Mesna; Biological: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Acute Lymphoblastic Leukemia; Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Dasatinib; Drug: Methotrexate; Drug: Ara-C
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Hodgkin's Lymphoma
Interventions: Drug: Adriamycin, Vinblastine, Vincristine, Bleomycin, Etoposide, Nitrogen Mustard (Cyclophosphamide), Prednisone; Procedure: Radiotherapy; Drug: Etoposide, Nitrogen Mustard (Cyclophosphamide) , Vincristine, Vinblastine, Adriamycin, Bleomycin, Prednisone
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012 - Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007 - Condition: Breast Cancer
Interventions: Biological: sargramostim; Biological: therapeutic autologous dendritic cells; Biological: trastuzumab; Drug: vinorelbine ditartrate
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Testicular Cancer; Germ Cell Neoplasm
Intervention: Drug: paclitaxel, gemcitabine, and oxaliplatin
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic
Interventions: Drug: Etoposide, cytarabine, vincristine, dexamethasone; Drug: methotrexate, teniposide, PEG-asparaginase; Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine; Drug: L-asparaginase, erwinia asparaginase; Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy; Procedure: Hematopoietic Stem Cell Transplant; Procedure: Natural Killer (NK) Cell Transplant
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2008 - Condition: Breast Cancer
Interventions: Drug: paclitaxel; Genetic: microarray analysis; Procedure: biopsy; Procedure: neoadjuvant therapy; Drug: Paclitaxel
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: lomustine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Hospital of Philadelphia
Recruiting - verified June 2009 - Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011 - Conditions: AIDS Related Lymphoma; HIV Infection
Interventions: Biological: Rituximab; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cysticercosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012


